logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Entos Raises $53 Million Series A Round Led By Coatue And Catalio

Entos Raises $53 Million Series A Round Led By Coatue And Catalio

07/14/21, 11:37 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan diego
Money raised
$53 million
Round Type
series a
Entos, Inc (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, today announced the closing of a $53 million Series A financing round led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.

Company Info

Company
Entos
Location
san diego, california, united states
Additional Info
Founded in 2019 and headquartered in San Diego, California, Entos is focused on disrupting therapeutic discovery with OrbNet, its cutting-edge platform combining AI-driven technology and automated synthetic development to rapidly design small-molecule therapeutics. Driven by technology derived from Caltech and the University of Bristol, Entos’ team is comprised of renowned scientists and engineers – including Chemistry Nobel Prize winner Frances Arnold – with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry. Learn more about Entos’ industry-revolutionizing platform at www.entos.ai.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.